How do accelerated approval pathways affect pipeline strategy?

Accelerated approval based on surrogate endpoints allows earlier market entry (often 2-3 years ahead of traditional approval) but requires confirmatory trials. The FDA has increased enforcement of post-marketing commitments, withdrawing 7 accelerated approvals in 2023-2024 when sponsors failed to verify clinical benefit. This has made sponsors more selective about pursuing the pathway.